TLR7 and neoplasm: In this study, we first developed a multifunctional nanoplatform based on mesoporous hexagonal core–shell zinc porphyrin-silica nanoparticles (MPSNs) loaded with R837 (a toll-like receptor-7 agonist), which could be used to integrate PDT, PTT, and tumor-specific immunotherapy for breast cancer.